scispace - formally typeset
Search or ask a question
Institution

ACADIA Pharmaceuticals Inc.

CompanySan Diego, California, United States
About: ACADIA Pharmaceuticals Inc. is a company organization based out in San Diego, California, United States. It is known for research contribution in the topics: Pimavanserin & Receptor. The organization has 260 authors who have published 276 publications receiving 8418 citations.


Papers
More filters
Journal ArticleDOI
TL;DR: In this article, a library of amides, synthesised by mixing acyl chlorides and diamines, was transformed into the corresponding thioamides using Lawesson's reagent as the oxygen/sulphur exchange reagent.

45 citations

Journal ArticleDOI
08 Jan 2004-Oncogene
TL;DR: A novel cellular proliferation assay for examining signal transduction to Rap utilizing Ras–rap chimeras that respond selectively to Rap-specific exchange factors, but which stimulate cellular proliferation through Ras effectors indicates that GPCRs coupled to pertussis-toxin-sensitive G-proteins activate Rap through a Gα subunit, C3G, and Src-dependent pathway.
Abstract: Ras proteins mediate the proliferative effects of G-protein-coupled receptors (GPCRs), but the role of Rap proteins in GPCR signaling is unclear. We have developed a novel cellular proliferation assay for examining signal transduction to Rap utilizing Ras-rap chimeras that respond selectively to Rap-specific exchange factors, but which stimulate cellular proliferation through Ras effectors. Both the D1 dopamine receptor (Gs-coupled) and the 5HT1E serotonin receptor (Gi-coupled) mediated cellular proliferation in a Ras/rap chimera-dependent manner. Responses to both receptors were PKA-independent. Both receptors activated Ras/rap and full-length Rap as measured by activation-specific probes. Pertussis toxin blocked Ras/rap-dependent responses to 5HT1E but not D1. Ras/rap-dependent responses to both receptors were insensitive to beta-gamma scavengers. Responses to 5HT1E, but not D1, were sensitive to inhibition by a dominant-negative C3G fragment, by the Src-like kinase inhibitors PP1 and PP2, and by a dominant-negative mutant of Src. Very similar data were obtained for two other Gi-coupled receptors, the D2 dopamine receptor and the alpha2C adrenergic receptor. A constitutively active mutant of Galphai2 also mediated Ras/rap-dependent responses. These data indicate that GPCRs coupled to pertussis-toxin-sensitive G-proteins activate Rap through a Galpha subunit, C3G, and Src-dependent pathway.

43 citations

Journal ArticleDOI
TL;DR: The sequential addition of Grignard reagents and aldehydes or ketones to pyridine N-oxides yields a complete regio- and stereoselective trans 2,3-addition reaction in high yields, and the substituted 2, 3-dihydropyridineN-oxide can be reduced to form 2,4-trans-substituted piperidines.
Abstract: Reactivity N - Own: Pyridine N-oxides can be used for the complete regio- and stereoselective synthesis of trans-substituted piperidines. The sequential addition of Grignard reagents and aldehydes or ketones to pyridine N-oxides yields a complete regio- and stereoselective trans 2,3- addition reaction in high yields, and the substituted 2,3-dihydropyridine N-oxide can be reduced to form 2,3-trans-substituted piperidines (see scheme).

42 citations

Journal ArticleDOI
TL;DR: The discovery and characterization of two structurally different, potent, selective, and metabolically stable small-molecule PAR-2 agonists are presented, which may be useful as pharmacological tools for elucidating the complex physiological role of thePAR-2 receptors as well as for the development of PAR- 2 antagonists.
Abstract: Proteinase activated receptor-2 plays a crucial role in a wide variety of conditions with a strong inflammatory component. We present the discovery and characterization of two structurally different, potent, selective, and metabolically stable small-molecule PAR-2 agonists. These ligands may be useful as pharmacological tools for elucidating the complex physiological role of the PAR-2 receptors as well as for the development of PAR-2 antagonists.

42 citations

Patent
26 Sep 2005
TL;DR: In this paper, the salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl), N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide of formula (I) including the citrate, fumarate, maleate, malate, phosphate, succinate, sulphate, and edisylate salts.
Abstract: Disclosed herein are salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide of formula (I) including the citrate, fumarate, maleate, malate, phosphate, succinate, sulphate, and edisylate salts.

42 citations


Authors

Showing all 261 results

Network Information
Related Institutions (5)
Eli Lilly and Company
22.8K papers, 946.7K citations

81% related

Pfizer
37.4K papers, 1.6M citations

81% related

AstraZeneca
23.4K papers, 938.2K citations

80% related

Merck & Co.
48K papers, 1.9M citations

80% related

Scripps Research Institute
32.8K papers, 2.9M citations

80% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20231
202119
202016
20196
20188
20176